Loibl Sibylle, Fersis Nicos, Harbeck Nadia
Breast Care (Basel). 2011 Dec;6(6):467-470. doi: 10.1159/000335477. Epub 2011 Dec 20.
Recently reported data from the German ZORO trial and the Italian PROMISE-GIM6 trial have come to different conclusions. The AGO Breast Commission does not recommend the general use of luteinizing hormone-releasing hormone (LHRH) analogues for the preservation of ovarian function. Instead, we distinguish between patients with hormone receptor-negative and hormone receptor-positive disease. This article reviews the AGO recommendations in light of the ZORO and PROMISE-GIM6 data. In conclusion, separate recommendations are needed for the prevention of ovarian failure and for fertility preservation because the trials did not investigate fertility rate as a primary outcome measure. The results from not yet published trials such as OPTION and POEM may shed new light on the role of LHRH analogues.
最近德国ZORO试验和意大利PROMISE - GIM6试验报告的数据得出了不同结论。AGO乳腺委员会不建议普遍使用促黄体生成素释放激素（LHRH）类似物来保留卵巢功能。相反，我们区分激素受体阴性和激素受体阳性疾病的患者。本文根据ZORO和PROMISE - GIM6的数据回顾了AGO的建议。总之，预防卵巢功能衰竭和保留生育能力需要分别提出建议，因为这些试验并未将生育率作为主要结局指标进行研究。尚未发表的试验如OPTION和POEM的结果可能会为LHRH类似物的作用带来新的启示。
